Form 4: Boston Scientific Director Sells Shares Under 10b5-1 Plan

Boston Scientific Director Ellen M. Zane sold 12,891 shares of common stock for $98.2839 per share under a pre-established trading plan.

Summary

• Ellen M. Zane, a Director of Boston Scientific Corp (BSX), reported a sale of common stock.
• The transaction involved 12,891 shares of BSX common stock.
• The shares were sold at a weighted average price of $98.2839 per share.
• The sale was executed on November 6, 2025.
• This transaction was conducted pursuant to a pre-established Rule 10b5-1 trading plan, which was adopted on July 25, 2025.
• Following this transaction, Ellen M. Zane directly beneficially owns 24,134 shares of Boston Scientific Corp common stock.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned insider stock sale, which is a routine disclosure and does not inherently indicate positive or negative sentiment about the company's future performance.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information.

Negatives

• A Director reduced their direct beneficial ownership of company common stock by 12,891 shares.

Risks

• No specific risks are disclosed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

This Form 4 does not provide any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.

Industry Context

This filing reports a routine insider transaction for Boston Scientific Corp and does not provide information relevant to broader industry trends or competitors.

Comparison to Industry Standards

• Not applicable, as this filing reports an individual insider stock transaction rather than company performance metrics.

Related Party Transactions

• The transaction involves a director of the company selling shares, which is a common type of insider transaction.

Stakeholder Impact

• Shareholders: A director's reduction in holdings could be perceived neutrally to slightly negatively, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Next Steps

• No specific future actions, events, or milestones are mentioned in this insider transaction report.

Key Dates

Recommendation

The Form 4 reports a pre-scheduled sale by a director under a 10b5-1 plan. This is a routine insider transaction and typically does not signal a change in the company's fundamentals or future prospects. Investors should consider broader company performance and market conditions rather than this single transaction for investment decisions.

Keywords

Boston Scientific, BSX, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan